Sun Pharma trades with traction on the bourses

Sun Pharmaceutical Industries is currently trading at Rs. 628.40, up by 12.20 points or 1.98% from its previous closing of Rs. 616.20 on the BSE. The scrip opened at Rs. 618.00 and has touched a high and low of Rs. 630.60 and Rs. 617.80 respectively. So far 180617 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 653.10 on 03-Mar-2014 and a 52 week low of Rs. 428.95 on 11-Apr-2013. Last one week high and low of the scrip stood at Rs. 643.20 and Rs. 571.00 respectively. The current market cap of the company is Rs. 130027.67 crore. The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.23% and 8.11% respectively. Sun Pharmaceutical Industries’ subsidiary Caraco has received US Food and Drug Administration (US FDA) approval for hypertension drug Microzide Generic. Microzide is used for treating high blood pressure. It is also used to treat fluid buildup in the body caused by certain conditions (eg, heart failure, liver cirrhosis, kidney problems) or medicines (eg, corticosteroids, estrogen). Earlier in March, Caraco received US FDA approval for Risperidone oral tablets. The oral tablet is used for the treatment of schizophrenia (a mental disorder). Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.